Literature DB >> 7104170

Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man.

C Von Bahr, J Hermansson, K Tawara.   

Abstract

1 We have given fifteen healthy volunteers single doses of racemic (+/-)-propranolol orally (40 mg) and intravenously (5-10 mg) to find out how large the variation was of the ratio between (-)- and (+)-propranolol plasma levels in relation to that of total levels of propranolol and 4-hydroxypropranolol. 2 Total propranolol (+/-)-levels 2 h after a 40 mg oral dose of (+/-)-propranolol varied from 21 to 580 nmol/l and those of 4-hydroxypropranolol from 0 to 33 nmol/l. Their levels did not correlate. The ratio between (-)- and (+)-propranolol levels varied from 0.99 to 2.04. The plasma half-lives of the two isomers were usually similar. 3 We conclude that in most single doses studies on relationships between plasma concentrations and effects (beta-adrenoceptor blockade) it is not necessary to quantitate (+)- and (-)-propranolol levels separately since total (+/-) plasma propranolol levels varied much more than the ratio between (-)- and (+)-propranolol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104170      PMCID: PMC1427572          DOI: 10.1111/j.1365-2125.1982.tb04937.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Spuriously low plasma propranolol concentrations resulting from blood collection methods.

Authors:  R H Cotham; D Shand
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

3.  The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol.

Authors:  A S Nies; G H Evans; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

4.  Pharmacokinetics of dextro-, laevo- and racemic propranolol in man.

Authors:  C F George; T Fenyvesi; M E Conolly; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

5.  Plasma concentrations of propranolol and 4-hydroxypropranolol in man measured by high pressure liquid chromatography.

Authors:  A M Taburet; A A Taylor; J R Mitchell; D E Rollins; J L Pool
Journal:  Life Sci       Date:  1979-01-15       Impact factor: 5.037

6.  Stereospecific radioimmunoassay for propranolol isomers.

Authors:  K Kawashima; A Levy; S Spector
Journal:  J Pharmacol Exp Ther       Date:  1976-02       Impact factor: 4.030

7.  Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol.

Authors:  J D Fitzgerald; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1971-09       Impact factor: 8.739

8.  Disposition of propranolol isomers in mice.

Authors:  A Levy; S H Ngai; A D Finck; K Kawashima; S Spector
Journal:  Eur J Pharmacol       Date:  1976-11       Impact factor: 4.432

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.

Authors:  T Walle; U K Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-03
View more
  15 in total

1.  Racial differences in drug response: isoproterenol effects before and after propranolol.

Authors:  D R Rutledge; A Wallace; J D Steinberg; L Cardozo; S J Lavine
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

2.  Evaluation of clinical bradycardiac effect and respiratory adverse effect of β-blocking agents in coronary computed tomography angiography based on theoretical analysis.

Authors:  Kaori Fujito; Risa Takayanagi; Koji Kimura; Haruko Yokoyama; Yasuhiko Yamada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-16       Impact factor: 2.441

3.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

Authors:  L Borgström; L Nyberg; S Jönsson; C Lindberg; J Paulson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 4.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 6.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.

Authors:  T Kaila; E Iisalo; A Lehtonen; H Saarimaa
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

8.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

9.  Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Authors:  H R Ochs; P Hajdú; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1986-07-15

10.  Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

Authors:  T Kaila; R Marttila
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.